Abstract: The present invention generally relates to compositions and methods for topical or transdermal delivery, for promoting wound healing, reducing scarring, and/or promoting hair growth. Specifically, the present disclosure is directed to a topical arginine silicate formulation that demonstrates surprising improvements in promoting hair growth.
Abstract: The present invention relates to a process for manufacturing (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid with the formula (Id) below and salts thereof The compound of formula (Id) is a prodrug of a catecholamine for use in treatment of neurodegenerative diseases and disorders such as Parkinson's Disease. The invention also relates to new intermediates of said process.
Type:
Grant
Filed:
August 2, 2021
Date of Patent:
December 26, 2023
Assignee:
H. Lundbeck A/S
Inventors:
Martin Juhl, Frans Dennis Therkelsen, Tobias Gylling Frihed
Abstract: The present invention provides an improved process for the preparation of Sugammadex sodium of formula (I) having more than 98.5% purity along with less than 1.0% monohydroxy Sugammadex sodium and less than 0.15% any other known or unknown impurities by HPLC.
Abstract: A packaging system for the storage of an ophthalmic device includes a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution comprising one or more crosslinked polymeric networks. The one or more crosslinked polymeric network comprises a reaction product of a first glycosaminoglycan, a second glycosaminoglycan, and a first crosslinking agent, wherein the first glycosaminoglycan is different than the second glycosaminoglycan. The aqueous packaging solution has an osmolality of at least about 180 mOsm/kg, a pH of about 6 to about 9 and is heat sterilized.
Type:
Grant
Filed:
June 21, 2022
Date of Patent:
December 19, 2023
Assignee:
Bausch & Lomb Incorporated
Inventors:
George L Grobe, III, Alok Kumar Awasthi, Mark R. Mis, Jennah L. Wolcott, James R. Hauenstein
Abstract: The present invention relates to methods of treating immune disorders and/or inflammation using certain modulator compounds. For example, the present invention provides methods of treating immune and/or inflammatory disorders by administering a composition comprising a compound having the structure of Formula (I).
Type:
Grant
Filed:
October 21, 2022
Date of Patent:
December 19, 2023
Assignees:
California Institute of Technology, Holoclara, Inc.
Inventors:
Brian M. Stoltz, Corey M. Reeves, Eduardo J. Martinez, Simon Bailey
Abstract: An anion exchange for separating a plurality of carbohydrates includes a negatively charged substrate particle. A base polymer layer includes a first plurality of quaternary amines. The polyalkylpolyamine polymer layer is covalently attached to the base condensation polymer layer. The polyalkylpolyamine polymer layer includes a polymeric branch structure that includes a second plurality of quaternary amines. A density of the second plurality of quaternary amines increases in a direction away from the base condensation polymer layer. The anion exchange stationary phase does not have a hydroxy group spaced apart from any one of the first or the second plurality of quaternary amines by an ethyl group.
Abstract: The disclosure provides compositions and methods related to activating alpha-kinase 1 (ALPK1) for modulating an immune response and treating or preventing cancer, infection, inflammation and related diseases and disorders as well as potentiating an immune response to a target antigen. The disclosure also provides heterocyclic compounds of formula (I) as agonists of alpha protein kinase 1 (ALPK1) and their use in activating ALPK1, modulating an immune response and treating diseases such as cancer, wherein A1, A2, L1, L2, L3, Z1, Z2, W1, W2, R1, R2, R3, R4, R5, R6 and R7 are defined herein.
Type:
Grant
Filed:
August 16, 2021
Date of Patent:
December 12, 2023
Assignee:
Shanghai Yao Yuan Biotechnology Co., Ltd.
Abstract: The present invention relates to conjugates of aminoglycosides and terpenoids, in particular sesquiterpenoids. Furthermore, the present invention relates to nano-assemblies formed by the inventive conjugates and to a method for producing the conjugates and/or the nano-assemblies. The present invention also relates to the inventive conjugates and nano-assemblies for use in therapy, in particular for use in the treatment of infectious diseases. Particularly preferred embodiments of the present invention relate to farnesylated aminoglycosides and nano-assemblies thereof, in which farnesol and its derivatives do not only function as carrier for the aminoglycosides but do themselves have pharmaceutical activity upon cleavage of the conjugate, in particular quorum sensing inhibitory activity.
Type:
Grant
Filed:
June 8, 2018
Date of Patent:
December 12, 2023
Assignee:
HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBH
Abstract: A cannabis-enriched enzymatically treated therapeutic composition. A therapeutic composition is described including water, glucose, glucose reaction product other than sucrose and fructose; a selected amount of a cannabinoid, a cannabinoid reaction product; optionally a terpene and optionally a terpene reaction product. Methods of making and using the compositions are also described.
Abstract: The present invention relates to pharmaceutical compounds, compositions and methods, especially as they relate to the treatment and/or prevention of conditions associated with activation of AMP-activated protein kinase, wherein the compound is of Formula (I): as described herein, including pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising such compounds, as well as methods to use these compositions for treating indications including cancer, diabetes, ischemic injury, obesity, hyperlipidemia, and cardiac conditions.
Abstract: A purification method of fungal cell wall composition includes following steps: (1) taking a residue of a fungus fruiting body underwent extraction process for obtaining extract thereof, wherein the extract contains terpenoids, sterols, polysaccharides, or a combination thereof, and the residue contains the cell wall of the fruiting body; (2) placing the residue into an aqueous percarbonate solution to form a mixture liquid, which is reacted at a first temperature for decolorizing the residue, wherein the concentration of the aqueous percarbonate solution ranges from 5 to 20% (w/v), and the first temperature ranges from 15 to 40° C.; (3) after the decolorization process, raising the temperature of the mixture liquid to a second temperature for the mixture liquid to react, so as to digest and decompose the residue, wherein the second temperature ranges from 80 to 100° C.; and (4) filtering the treated mixture liquid to obtain a purified product.
Abstract: [Problem] To develop a technique that can stabilize the higher-order structure of a nucleic acid and can be used in analysis of nucleic acid structure. [Solution] This guanosine derivative compound is represented by formula 1. In the formula, one of R1 and R2 represents H, and the other represents any of H, OH, OCH3, and F, R3 represents a functional group that is for detection and that has 19F, R4 represents an amine-protecting group, R5 represents a hydroxy group-protecting group, and R6 represents an introduction group that is to be introduced into a nucleic acid oligomer. This guanosine derivative compound can be introduced as a part of a nucleic acid sequence, and the introduced nucleic acid oligomer stabilizes the higher-order structure in a nucleic acid, and enables dynamic detection by 19F NMR.
Type:
Grant
Filed:
August 29, 2019
Date of Patent:
November 28, 2023
Assignee:
UNIVERSITY OF MIYAZAKI
Inventors:
Yan Xu, Takumi Ishizuka, Hong-Liang Bao
Abstract: Methods for treating and/or preventing HFpEF and/or at least one disease, disorder, and/or condition associated therewith in patients by the use of dapagliflozin and compositions comprising the same are disclosed.
Abstract: This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.
Type:
Grant
Filed:
April 3, 2023
Date of Patent:
November 28, 2023
Assignee:
Mandos LLC
Inventors:
Bernardus Nicolaas Machielse, Allan Darling
Abstract: A natural liquid composition is provided for disinfectant, antibacterial or anticorrosion applications. The natural liquid composition is an electrospun solubilized composition of natural chitosan (CS) and an FDA approved polymer polyvinyl alcohol (PVA). Two fillers, citric acid (CA) and ascorbic acid (AA), added anti-corrosion property to the composite nanofiber solution without affecting the other properties (disinfectant and antibacterial) and have a final synergistic effect of all components together in a final solution form. Embodiment of the invention advances the art by providing a natural solution to overcome at least some of the problems with the currently used agents.
Type:
Grant
Filed:
November 15, 2017
Date of Patent:
November 21, 2023
Assignee:
The American University in Cairo
Inventors:
Wael Mamdouh Sayed Sayed Ahmed, James Kegere
Abstract: Isolated heparin or heparan sulphate oligosaccharide fragments having a chain length of at least 10 saccharides and no more than 50 saccharides, which are capable of binding BMP2, are disclosed. Also disclosed is the use of the same heparin or heparan sulphate oligosaccharide fragments in kits and pharmaceutical compositions, and the use of the same heparan sulphate oligosaccharide fragments in the repair and/or regeneration of connective tissue and bones, and the treatment of wounds.
Type:
Grant
Filed:
April 25, 2022
Date of Patent:
November 7, 2023
Assignee:
Agency for Science, Technology and Research
Inventors:
Raymond Alexander Alfred Smith, Simon McKenzie Cool, Victor Nurcombe, Sadasivam Murali
Abstract: A method of treating viral infection, such as viral infection caused by a virus of the Coronaviridae family, is provided. A composition having at least oleandrin or digoxin is used to treat the viral infection or the disease state of said viral infection.
Type:
Grant
Filed:
December 17, 2021
Date of Patent:
November 7, 2023
Assignee:
PHOENIX BIOTECHNOLOGY, INC.
Inventors:
Robert A. Newman, Otis C. Addington, Jose R. Matos, Richard J. Obiso
Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
Type:
Grant
Filed:
March 17, 2022
Date of Patent:
November 7, 2023
Assignee:
ORIC PHARMACEUTICALS, INC.
Inventors:
Xiaohui Du, John Eksterowicz, Valeria R. Fantin, Daqing Sun, Qiuping Ye, Jared Moore, Tatiana Zavorotinskaya, Brian R. Blank, Yosup Rew, Kejia Wu, Liusheng Zhu, Johnny Pham, Hiroyuki Kawai
Abstract: A method for preparing an intermediate by a reduced glutathione-indicated amino acid Maillard reaction is provided. The method includes a two-stage reaction at an increased temperature. A reduced glutathione is added after different times of a low-temperature reaction, and a subsequent Maillard reaction is effectively inhibited on a basis wherein a substance is interacted with an intermediate degradation product to reduce a formation of colored substances. Comparing with a browning of Maillard products after a high-temperature stage, a reaction time with a best color inhibition effect is found to be the optimal preparation condition of the intermediate, and the intermediate is prepared in an aqueous medium at a low temperature under this optimal preparation condition. The method uses the water soluble reduced glutathione as a tracer to improve a tracing accuracy comparing to cysteine.
Abstract: The present document describes a process for the preparation of a low functionalization polysaccharide having carboxyl groups, comprising a) swelling of a polysaccharide granule in boiling water or a water/polyol mixture, to obtain a swollen polysaccharide; b) partial gelatinization of said swollen polysaccharide in an alkaline solvent mixture of water and alcohol and/or polyol, to obtain a partially gelatinized polysaccharide; and c) partial functionalization of said partially gelatinized polysaccharide with a functionalizing agent, to obtain the low functionalization polysaccharide.